Dr. Roboz on Challenges With CAR T-cell Therapy in ALL

Gail Roboz, MD
Published: Friday, Aug 04, 2017



Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

CAR T-cell therapy has been an interesting and exciting treatment modality, but it is not yet curing patients, Roboz explains. One of its major limitations has been for patients who have received multiple other therapies, since they may not be in an ideal condition to either deliver T cells or to wait until their own T cells are engineered. For some patients, they may also experience disease progression in 3 months or so until those cells are available. Overall, it's a therapeutic modality with some logistical difficulties associated with it, she adds.

Researchers are working to make inroads into earlier phases of ALL so that they are not waiting until patients have relapsed disease and when they are more difficult to treat.


Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

CAR T-cell therapy has been an interesting and exciting treatment modality, but it is not yet curing patients, Roboz explains. One of its major limitations has been for patients who have received multiple other therapies, since they may not be in an ideal condition to either deliver T cells or to wait until their own T cells are engineered. For some patients, they may also experience disease progression in 3 months or so until those cells are available. Overall, it's a therapeutic modality with some logistical difficulties associated with it, she adds.

Researchers are working to make inroads into earlier phases of ALL so that they are not waiting until patients have relapsed disease and when they are more difficult to treat.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x